Vfend

(voriconazole)

ApprovedSmall molecule

Voriconazole is used to treat serious fungal infections, including aspergillosis and candidiasis. It works by stopping the growth of fungal organisms that cause these infections.[2] Vfend is currently approved and in use across 20 indications[4].[1]

Vfend is one of 372 small molecule programs targeting Systemic Mycosis. It is currently in Approved.

Indications

100

Total Trials

Active Trials

371

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Systemic MycosisActive, not recruiting

Breast CancerActive, not recruiting

Non-Melanoma Skin CarcinomaActive, not recruiting

ConcentrationTerminated

FusariosisActive, not recruiting

Fungal Infectious DiseaseActive, not recruiting

Chronic Lymphocytic LeukemiaApproved

Kidney FailureApproved

LeishmaniasisApproved

Lymphoid NeoplasmApproved

Systemic MycosisPreclinical

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Non-Melanoma Skin CarcinomaPreclinical

Active, not recruiting

ConcentrationPreclinical

Terminated

FusariosisApproved

Active, not recruiting

Fungal Infectious DiseaseApproved

Active, not recruiting

Chronic Lymphocytic LeukemiaApproved

Approved

Kidney FailureApproved

Approved

LeishmaniasisApproved

Approved

Lymphoid NeoplasmApproved

Approved

Showing 10 of 20 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Vfend

PPrism Pharmaceuticals

Adenocard

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Epilepsy

NCT07156201

Clinical

Trials by Indication[1]

Aspergillosis13 trials

Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

Withdrawn· Pfizer logo

Pfizer·Phase 3·NCT01188759

Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003031·212 enrolled

Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001646·10 enrolled

Show 10 more trials

Voriconazole For Chronic Bronchopulmonary Aspergillosis

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT00159822·48 enrolled

Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

Terminated·SScynexis, Inc.·Phase 2·NCT03672292·22 enrolled

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

Completed· Astellas logo

Astellas·Phase 3·NCT00412893·527 enrolled

A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00836875·31 enrolled

Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00059878

A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis

Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT04824417·116 enrolled

A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01782131·585 enrolled

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis

Withdrawn· Astellas logo

Astellas·Phase 4·NCT00423163

Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

Terminated· Pfizer logo

Pfizer·Phase 4·NCT00620074·6 enrolled

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Completed· Pfizer logo

Pfizer·Phase 3·NCT00531479·459 enrolled

Fungal Infection7 trials

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection

Completed· Pfizer logo

Pfizer·Phase 2·NCT01383993·21 enrolled

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)

Completed·MMedical College of Wisconsin·Phase 3·NCT00075803·600 enrolled

A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections

Completed· Pfizer logo

Pfizer··NCT00721578·23 enrolled

Show 4 more trials

Voriconazole to Prevent Systemic Fungal Infections in Children

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00005912·48 enrolled

Voriconazole to Treat Fungal Infections

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00001940·100 enrolled

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

Completed· Pfizer logo

Pfizer·Phase 2·NCT00739934·40 enrolled

A Pilot Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

Completed·NNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 1·NCT00353158·62 enrolled

Invasive Fungal Infections6 trials

Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants

Completed· Pfizer logo

Pfizer·Phase 4·NCT00143312·45 enrolled

Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00015665·40 enrolled

Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00238355·13 enrolled

Show 3 more trials

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001757·20 enrolled

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00418951·120 enrolled

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00001810·300 enrolled

Interaction3 trials

Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01787032·20 enrolled

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

Terminated· Gilead logo

Gilead·Phase 1·NCT05458102·18 enrolled

Study on the Drug Interaction Between Buagafuran and Voriconazole

Not yet recruiting·BBeijing Union Pharmaceutical Factory Ltd·Phase 1·NCT07457203·18 enrolled

Treatment3 trials

Mycotic Ulcer Treatment Trial I

Completed·UUniversity of California, San Francisco·Phase 3·NCT00996736·323 enrolled

Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients

Completed· Pfizer logo

Pfizer·Phase 3·NCT00150345·147 enrolled

Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

Completed·AAsahi Kasei Pharma Corporation·Phase 3·NCT03471988·103 enrolled

49 more indications

Safety and Efficacy3 trials

Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02180165·116 enrolled

The Influence of CYP2C19 Polymorphisms on the Safety and Efficacy of Voriconazole

Unknown status·—··NCT04547335·34 enrolled

Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet In Korea

Completed· Pfizer logo

Pfizer··NCT01073631·543 enrolled

Drug Interactions3 trials

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00833482·185 enrolled

Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT02576366·24 enrolled

Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole

Completed·SSeoul National University Hospital·Phase 1·NCT01080651·12 enrolled

Concentration3 trials

Study of Cyclodextrin (SBECD) and Voriconazole Blood Concentrations During Continuous Dialysis

Completed·UUniversity of Colorado, Denver··NCT01101386·10 enrolled

Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration

Terminated·UUniversity of Aarhus·N/A·NCT02396225·12 enrolled

CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients

Unknown status·Ddingshifang··NCT02100761·200 enrolled

Children2 trials

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00174473·49 enrolled

Population Pharmacokinetics of Anti-infectious Drugs in Children

Completed·UUniversity Hospital, Bordeaux·N/A·NCT01344512·214 enrolled

Candidiasis2 trials

Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study

Completed· Pfizer logo

Pfizer·Phase 3·NCT00689338·216 enrolled

This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis

Completed· Pfizer logo

Pfizer·Phase 4·NCT00548262·54 enrolled

Efficacy and Safety2 trials

A Study To Assess The Efficacy And Safety Of Voriconazole In Chinese Patients With Serious Deep Tissue Fungal Infections

Completed· Pfizer logo

Pfizer·Phase 4·NCT00288197·77 enrolled

A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections

Completed· Pfizer logo

Pfizer·Phase 4·NCT00647907·7 enrolled

Tics2 trials

Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy

Completed·MMartin-Luther-Universität Halle-Wittenberg·Phase 4·NCT01539330·9 enrolled

Influence of CYP2C19 Genotype on the Pharmacokinetics (PK) of Voriconazole

Completed·SSeoul National University Hospital·Phase 1·NCT00942773·18 enrolled

Liver2 trials

Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers

Completed·IIndiana University·N/A·NCT01104376·61 enrolled

Clinical Assessment of Voriconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel

Completed·SSara Botros·Phase 2·NCT04110860·30 enrolled

Graft Versus Host Disease2 trials

Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease

Completed·PPhillip Brian Smith·Phase 1·NCT00792246·5 enrolled

Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT01950507·15 enrolled

AIN2 trials

Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy

Completed· Pfizer logo

Pfizer·Phase 1·NCT00136968·12 enrolled

To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days

Completed· Pfizer logo

Pfizer·Phase 4·NCT00300677·12 enrolled

Acute Myeloid Leukemia2 trials

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed· Astellas logo

Astellas·Phase 1/2·NCT02014558·265 enrolled

Short-Term Outcome of Newly Diagnosed Acute Myeloid Leukemia Treated With Hypomethylating Agents and Venetoclax in Patients Ineligible for Intensive Chemotherapy: A Single-Centre Prospective Study

Completed·BBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh·Approved·NCT07773909·24 enrolled

Hematologic Malignancy2 trials

Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy

Terminated·—··NCT01148160·10 enrolled

Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy

Unknown status·—··NCT04743544·62 enrolled

Systemic1 trial

Registry of Patients Treated With Systemic Mold-Active Triazoles

Completed· Astellas logo

Astellas··NCT03066011·2,015 enrolled

Randomized1 trial

The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

Completed·UUniversity of California, San Francisco·Phase 3·NCT00997035·240 enrolled

Prophylaxis1 trial

Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00904995·23 enrolled

Immunocompromised1 trial

A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents

Completed· Pfizer logo

Pfizer·Phase 2·NCT00556998·26 enrolled

LAL1 trial

The Study of Voriconazole Trough Level in the First Two Weeks After Administration in King Chulalongkorn Memorial Hospital.

Unknown status·—··NCT03260634·92 enrolled

Stem Cell Transplant1 trial

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

Completed·CChildren's Oncology Group·Phase 3·NCT01503515·292 enrolled

B-cell Malignancies1 trial

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

Completed· BeiGene logo

BeiGene·Phase 1·NCT04551963·26 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Completed·JJonsson Comprehensive Cancer Center·N/A·NCT00079222

Candidemia1 trial

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Completed· Astellas logo

Astellas·Phase 3·NCT00413218·450 enrolled

Single Dose1 trial

A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06493409·32 enrolled

Malignancies1 trial

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT04865419·46 enrolled

Allergic Bronchopulmonary Aspergillosis1 trial

Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis

Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT01621321·50 enrolled

Blastomycosis1 trial

Amphotericin-B and Voriconazole for Pulmonary Blastomycosis

Terminated·UUniversity of Manitoba·Phase 4·NCT02283905·2 enrolled

Pediatric Patients1 trial

A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients

Terminated· Pfizer logo

Pfizer·Phase 3·NCT01092832·23 enrolled

Lung Transplant Recipient1 trial

Voriconazole as Prophylactic Therapy in Lung Transplant Recipients

Terminated·UUniversity of Chicago·Phase 4·NCT00455364·20 enrolled

Stem Cell Transplant Patients1 trial

MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT02227797·66 enrolled

Corneal Ulcer1 trial

Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT00557362·120 enrolled

Neutropenia1 trial

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00066599

Skin Cancer1 trial

Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

Completed· Pfizer logo

Pfizer··NCT01480219·467 enrolled

Cryptococcal Meningitis1 trial

Three Induction Treatments on Cryptococcal Meningitis

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 1·NCT04072640·120 enrolled

Pilot Study1 trial

Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent

Withdrawn·KKenneth Hargreaves·Phase 2·NCT02689713

Efficacy1 trial

Efficacy of Voriconazole Loaded Spanlastics Gel Versus Clotriamazole Cream on Treating Vulvovaginal Candidasis

Completed·—··NCT06392529·28 enrolled

Invasive Fungal Infection1 trial

Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection

Completed· Pfizer logo

Pfizer··NCT01137292·177 enrolled

Asthma1 trial

Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects

Completed·ZZambon SpA·Phase 1·NCT04229303·58 enrolled

Drug Monitoring1 trial

Therapeutic Drug Monitoring of Voriconazole

Completed·SSeoul National University Hospital·N/A·NCT00890708·110 enrolled

ESS1 trial

A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen

Completed·SSeoul National University Hospital·Phase 1·NCT03760276·11 enrolled

COPD1 trial

Voriconazole for IPA in Chinese Patients With COPD

Unknown status·—·Phase 4·NCT02234739·40 enrolled

Chronic Graft Versus Host Disease1 trial

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT04294641·10 enrolled

Female1 trial

A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT00855101·35 enrolled

Dexamethasone1 trial

Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects

Not yet recruiting·MMin Kyu Park·Phase 1·NCT07426042·12 enrolled

TED1 trial

Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status

Unknown status·UUniversity Hospital, Geneva·Phase 1·NCT05264142·45 enrolled

B-cell Malignancy1 trial

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02381080·26 enrolled

Leukemia1 trial

Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia

Terminated·UUniversity of Cologne·Phase 3·NCT00152594·150 enrolled

Drug1 trial

Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Completed· Pfizer logo

Pfizer··NCT01151085·1,002 enrolled

Immunodeficiency1 trial

Comparative Study of Human Immunodeficiency Virus Negative Host Talaromyces Between Voriconazole and Amphotericin Sequential Itraconazole Therapy

Unknown status·GGuangxi Medical University·N/A·NCT03827278·200 enrolled

Epilepsy1 trial

A First-in-Human, Phase 1a, Randomized, Double-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose and Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Administered Orally to Healthy Adults

Recruiting·AActio Biosciences, Inc.·Phase 1·NCT07156201·92 enrolled

Unspecified5 trials

Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan)

Completed· Pfizer logo

Pfizer··NCT01660334·13 enrolled

Blood and Marrow Transplant Clinical Research Network

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT00023530

Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend)

Completed·SSamyang Biopharmaceuticals Corporation·Phase 1·NCT01657201·59 enrolled

Show 2 more trials

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

Completed·GGalapagos NV·Phase 1·NCT03515382·18 enrolled

Pharmacologic Optimization of Voriconazole

Completed·JJan-Willem C Alffenaar·Phase 3·NCT00893555·189 enrolled

Regulatory

FDA Approval Timeline[5]

May 24, 2002

VFEND

NDA NDA021267

May 24, 2002

VFEND

NDA NDA021266

Dec 19, 2003

VFEND

NDA NDA021630

Mar 9, 2017

VORICONAZOLE

NDA NDA208562

Sources

References

[1]
ClinicalTrials.gov — 100 trial records for voriconazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Vfend drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — voriconazole compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for voriconazole. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA208562). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Prism Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cytochrome P450 51 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: PPrism Pharmaceuticals

Vfend

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Aspergillosis13 trials

Fungal Infection7 trials

Invasive Fungal Infections6 trials

Interaction3 trials

Treatment3 trials

Safety and Efficacy3 trials

Drug Interactions3 trials

Concentration3 trials

Children2 trials

Candidiasis2 trials

Efficacy and Safety2 trials

Tics2 trials

Liver2 trials

Graft Versus Host Disease2 trials

AIN2 trials

Acute Myeloid Leukemia2 trials

Hematologic Malignancy2 trials

Systemic1 trial

Randomized1 trial

Prophylaxis1 trial

Immunocompromised1 trial

LAL1 trial

Stem Cell Transplant1 trial

B-cell Malignancies1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Candidemia1 trial

Single Dose1 trial

Malignancies1 trial

Allergic Bronchopulmonary Aspergillosis1 trial

Blastomycosis1 trial

Pediatric Patients1 trial

Lung Transplant Recipient1 trial

Stem Cell Transplant Patients1 trial

Corneal Ulcer1 trial

Neutropenia1 trial

Skin Cancer1 trial

Cryptococcal Meningitis1 trial

Pilot Study1 trial

Efficacy1 trial

Invasive Fungal Infection1 trial

Asthma1 trial

Drug Monitoring1 trial

ESS1 trial

COPD1 trial

Chronic Graft Versus Host Disease1 trial

Female1 trial

Dexamethasone1 trial

TED1 trial

B-cell Malignancy1 trial

Leukemia1 trial

Drug1 trial

Immunodeficiency1 trial

Epilepsy1 trial

Unspecified5 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News